Silvio E Inzucchi
Overview
Explore the profile of Silvio E Inzucchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
416
Citations
25094
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Abdin A, Kondo T, Bohm M, Jhund P, Claggett B, Vaduganathan M, et al.
Eur J Heart Fail
. 2024 Jul;
26(9):1952-1963.
PMID: 39016033
Aims: The primary aim was to evaluate the effect of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction (LVEF), given that prolongation of QRS duration...
12.
Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, et al.
Cardiovasc Diabetol
. 2024 Jul;
23(1):248.
PMID: 38992713
Background: The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods: This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME...
13.
Apperloo E, Neuen B, Fletcher R, Jongs N, Anker S, Bhatt D, et al.
Lancet Diabetes Endocrinol
. 2024 Jul;
12(8):545-557.
PMID: 38991584
Background: SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are...
14.
Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Pocock S, et al.
Diabetes Res Clin Pract
. 2024 May;
212:111715.
PMID: 38777127
In EMPA-REG OUTCOME, empagliflozin reduced the composite of total events leading to/prolonging hospitalisation for any cause and all-cause mortality by 24 % versus placebo in patients with T2DM and ASCVD,...
15.
Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, et al.
Eur J Heart Fail
. 2024 May;
26(7):1539-1548.
PMID: 38745498
Aims: Type 2 diabetes (T2D) and heart failure (HF) frequently coexist, but whether clinical outcomes and treatment effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) vary in relation to background glucose-lowering...
16.
Yang M, Kondo T, Talebi A, Jhund P, Docherty K, Claggett B, et al.
Eur J Heart Fail
. 2024 May;
26(7):1524-1538.
PMID: 38700986
Aims: Although much is known about the usefulness of heart failure (HF)-specific instruments for assessing patient well-being, less is known about the value of generic instruments for the measurement of...
17.
Pabon M, Wang X, Lam C, OMeara E, Vaduganathan M, Claggett B, et al.
JACC Heart Fail
. 2024 Apr;
12(6):1119-1122.
PMID: 38661586
No abstract available.
18.
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, et al.
J Am Heart Assoc
. 2024 Apr;
13(9):e033322.
PMID: 38639369
Background: The implementation of preventive therapies among patients with stroke remains inadequately explored, especially when compared with patients with myocardial infarction (MI), despite sharing similar vascular risk profiles. We tested...
19.
Patel S, Kang Y, Im K, Neuen B, Anker S, Bhatt D, et al.
Circulation
. 2024 Apr;
149(23):1789-1801.
PMID: 38583093
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear. Methods: This was...
20.
Butt J, Jhund P, Docherty K, Claggett B, Vaduganathan M, Bachus E, et al.
JACC Heart Fail
. 2024 Apr;
12(9):1586-1599.
PMID: 38573262
Background: Patients recently hospitalized for heart failure (HF) are at a higher risk of adverse clinical outcomes, but they may experience a greater absolute and relative benefit from effective therapies...